Get the Stockscreener App
19.36
0.10%
0.02
Pre-market:
19.57
0.21
+1.08%
Schrodinger Inc stock is traded at $19.36, with a volume of 2.55M.
It is up +0.10% in the last 24 hours and down -6.16% over the past month.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
See More
Previous Close:
$19.34
Open:
$20.31
24h Volume:
2.55M
Relative Volume:
2.23
Market Cap:
$1.24B
Revenue:
$193.35M
Net Income/Loss:
$-177.58M
P/E Ratio:
-7.902
EPS:
-2.45
Net Cash Flow:
$-172.43M
1W Performance:
-4.77%
1M Performance:
-6.16%
6M Performance:
-24.58%
1Y Performance:
+7.26%
1-Day Range:
$18.48
$20.31
1-Week Range:
$18.48
$20.31
52-Week Range:
$16.60
$28.47
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
19.36 | 1.42B | 193.35M | -177.58M | -172.43M | -2.45 |
|
VEEV
Veeva Systems Inc
|
279.76 | 46.19B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
58.74 | 9.61B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
58.55 | 10.89B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
91.84 | 7.86B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
33.91 | 5.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrodinger, Inc. Earnings Call: Growth Amid Challenges - TipRanks
Citi Affirms Buy Rating on Schrödinger (SDGR) amid Expanded Collaboration with Ajax Therapeutics - MSN
Schrödinger maintains 10–15% software revenue growth guidance while advancing SGR-1505 clinical program - MSN
Earnings call transcript: Schrodinger beats Q2 2025 forecasts, stock dips - Investing.com
Schrödinger, Inc. Reports Strong Q2 2025 Results - TipRanks
Decoding Schrodinger Inc (SDGR): A Strategic SWOT Insight - GuruFocus
Schrödinger's Dual-Track Strategy: Software Growth and Clinical Pipeline Progress - AInvest
Schrödinger's Q2 2025: Unpacking Contradictions in Customer Engagement, Toxicology Feedback, and Revenue Confidence - AInvest
Schrödinger, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:SDGR) - Seeking Alpha
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Schrödinger (SDGR) Q2 2025 Earnings Transcript - Mitrade
Schrodinger Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Schrödinger Q2 2025 slides: Revenue grows 16% as company maintains full-year guidance By Investing.com - Investing.com South Africa
Schrödinger Q2 2025 slides: Revenue grows 16% as company maintains full-year guidance - Investing.com
Schrodinger earnings beat by $0.15, revenue topped estimates - Investing.com India
Schrodinger Inc (SDGR) Q2 2025 Earnings: EPS of -$0.59 Beats Estimate, Revenue Surpasses Forecast at $54.8 Million - GuruFocus
Schrödinger Reports Second Quarter 2025 Financial Results - Yahoo Finance
Earnings To Watch: Schrodinger Inc (SDGR) Reports Q2 2025 Result - Yahoo Finance
What drives Schrödinger Inc. stock priceInvest smarter with real-time trading alerts - Jammu Links News
What are the technical indicators suggesting about Schrödinger Inc.Get real-time updates on market trends - Jammu Links News
Does Schrödinger Inc. stock perform well during market downturnsBuild a winning investment strategy - Jammu Links News
How volatile is Schrödinger Inc. stock compared to the marketGet exclusive access to expert stock recommendations - Jammu Links News
What catalysts could drive Schrödinger Inc. stock higher in 2025Record-breaking capital gains - Jammu Links News
Is Schrödinger Inc. a good long term investmentTriple-digit growth rates - Jammu Links News
When is Schrödinger Inc. stock expected to show significant growthBreakout profit opportunities - Jammu Links News
Is Opendoor Technologies a Millionaire-Maker Stock? - The Globe and Mail
Will Schrödinger Inc. outperform the marketGrowth Focused Entry Plan Suggestions Issued - metal.it
Live Scanner Shows Breakout on Schrödinger Inc.Low Risk Picks for Daily Trading Released - metal.it
Is Schrödinger's (SDGR) Expanded Ajax Partnership Shaping Its Drug Discovery Revenue Potential? - simplywall.st
Screener Results Flag Schrödinger Inc. as OversoldTarget Return Focused Trade Insights Shared - beatles.ru
Is Schrödinger Inc. stock overvalued or undervaluedUnlock steady growth with low-risk stocks - Jammu Links News
Schrodinger SDGR Q2 2025 Earnings Preview Upside Potential on Strong Software Revenue Growth - AInvest
How many analysts rate Schrödinger Inc. as a “Buy”Unlock daily market insights for better trades - Jammu Links News
Is Schrödinger Inc. a growth stock or a value stockMaximize returns with strategic trading plans - Jammu Links News
What makes Schrödinger Inc. stock price move sharplyTriple Return With Stability - metal.it
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 - 01net
Schrödinger to Announce Second Quarter 2025 Financial Results on August 6 | SDGR Stock News - GuruFocus
What analysts say about Schrödinger Inc. stockUnmatched market gains - Autocar Professional
Is Schrödinger Inc. stock overhyped or has real potentialExceptional profit velocity - Jammu Links News
Schrödinger Inc. Stock Analysis and ForecastDynamic growth stocks - PrintWeekIndia
Schrodinger, Inc. (SDGR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - MSN
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Schrodinger Inc Stock (SDGR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Akinsanya Karen | President of R&D, Therapeutics |
Apr 14 '25 |
Sale |
25.09 |
16,723 |
419,570 |
15,625 |
1.49%
1.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):